Synergistic anticancer theragnostic study of a core-shell structured galvanic cell

The chemodynamic therapy (CDT) effect is restricted by the neutral pH environment in the tumor, also, the protein corona formed on the surface of the CDT catalyst reduces its activity. Here, we synthesized a core-shell CDT drug consisting of Fe/Fe3C core and mesoporous graphite carbon shell with biotin modification (denoted FeCNB). The shell and core form a galvanic cells in the physiological electrolyte solution to achieve highefficiency CDT under physiological pH conditions. The mesoporous in the shell effectively separates the protein corona from the Fe/Fe3C, avoiding the influence of the protein corona on the catalyst. However, the mesoporous is permeable for the substrate and product of the catalytic reaction. FeCNB also has T2-magnetic resonance imaging (MRI) function and photothermal conversion ability under 808 nm laser irradiation. The tumor heating further improves the CDT effect to achieve a satisfactory synergistic photothermal therapy (PTT)/ CDT outcome. In addition, FeCNB degrades in the microenvironment to ensure its excellent biocompatibility. It is the first study of CDT drug design and fabrication based on the mechanism of the galvanic cells.

Automated summary

Researchers have successfully synthesized a core-shell CDT drug FeCNB, which achieves high-efficiency CDT under physiological pH conditions through the galvanic cell structure formed in physiological electrolyte solution. FeCNB not only has T2-magnetic resonance imaging function and photothermal conversion ability, but also improves the CDT effect through tumor heating to achieve a satisfactory synergistic photothermal therapy (PTT)/CDT outcome.